Company profile
Surrozen, Inc.
NASDAQ: SRZN · Healthcare · Biotechnology
#737 of 1,417 Healthcare companies by revenuebottom-quartile growth
EA Score
30DFH 20DQ 46GM 17SS 47
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ net margin, revenue growth (YoY)
Methodology →Revenue TTM
$7.5M
Rev growth YoY (TTM)
-35.6%
Net income (FY)
-$242.0M
Employees
44
as of 2026-08-14
Market cap
$177.4M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.5M$3.5M2025
Net income-$242.0M-$242.0M2025
Operating income-$42.1M-$42.1M2025
Total assets$98.7M$98.7M2025
Liabilities$286.5M$286.5M2025
Equity-$187.8M-$187.8M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration and license revenue0%
By geography
UNITED STATES100%
The read
What is Surrozen, Inc.’s revenue?
Surrozen, Inc. booked $3.5M in FY2025 revenue, contracting 67% year over year — slower than 86% of Healthcare companies we track, at a -6960.8% net margin.
Peers · Healthcare
Revitalist Lifestyle and Wellness Ltd.——SheerVision, Inc.——CAMP4 Therapeutics Corporation27DTelescope Innovations Corp.——Caliber Imaging & Diagnostics, Inc.——United American Healthcare Corporation——Neighbors
San Mateo →Key facts
CEOCraig Parker
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: SRZN
Employees44
IPO date2021-01-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.